PMH49 Evaluation of health related quality of life outcomes among patients with schizophrenia switched to lurasidone from other antipsychotics  by Awad, G. et al.
A64 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
stop thinking about your problems?” The item “how much have you looked 
forward to things with enjoyment?” was changed to “how much of the time did 
you feel enjoyment?”, and “how much have you felt useful?” was revised to read 
“how much of the time did you feel useful?” CONCLUSIONS: When 
translatability assessment is conducted prior to the finalization of a new 
measure, language changes can be implemented that will facilitate translation 
and cross cultural adaptation. When difficulties are encountered that may not 
warrant changes on their own, results from translatability assessments can also 
be useful in adding awareness and greater weight to other aspects of item 
structure that might need to be altered to improve the integrity and quality of 
the measure.  
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OBJECTIVES: Patients with schizophrenia frequently switch between 
antipsychotics, underscoring the need to ensure that important treatment 
outcomes such as health-related quality of life (HRQL) are achieved and 
maintained following the switch. This analysis evaluated changes in overall 
health-related quality of life among patients with schizophrenia switched from 
current antipsychotic treatment to lurasidone. METHODS: Stable, but 
symptomatic outpatients with schizophrenia were switched from their current 
antipsychotic to lurasidone, in a 6-week, open-label trial, conducted in the US. 
The Personal Evaluation of Transitions in Treatment (PETiT) is a validated 30-
item instrument measuring self-reported overall quality of life outcomes among 
patients with schizophrenia. In addition, PETiT assesses two domain scores on 
psychosocial functioning and adherence related attitude. Higher scores on PETiT 
denote better HRQL. PETiT scale was administered at baseline and study 
endpoint. Changes from baseline to study endpoint in PETiT total score (overall 
HRQL) and domain scores (psychosocial functioning and adherence) were 
compared using ANCOVA with baseline score, treatment, and pooled site as 
covariates. RESULTS: Of the 244 patients switched to lurasidone from other 
antipsychotics, patients with available data on PETiT (n=213) were included in 
the analysis. Mean PETiT total scores at baseline was 35.3 and at study endpoint 
was 38.5. Mean change from baseline to the study endpoint in the PETiT total 
score was 3.2, change in psychosocial functioning domain score was 2.5, and 
change in adherence domain score was 0.7, significant in all patient groups 
(p<0.001). CONCLUSIONS: The findings from this study indicate that patients 
switching from other antipsychotics to lurasidone experienced statistically 
significant improvement in HRQL, psychosocial functioning and adherence 
related attitude within six weeks of treatment. Further investigation regarding 
the effects of longer-term lurasidone treatment on HRQL outcomes is warranted.  
 
PMH50  
CAREGIVER BURDEN AND SOCIAL SUPPORT IN FAMILIES OF CHILDREN WITH 
AUTISM: A LITERATURE REVIEW  
Shah D1, Giannetti V2, Pfalzgraf A1 
1Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA, USA, 2Duquesne University, 
Pittsburgh, PA, USA  
OBJECTIVES: Caregiver burden and social support play a crucial role in 
moderating the treatment outcomes of children with autism. It is important for 
health care services researchers to consider the impact of these constructs while 
understanding treatment outcomes. The goal of this study is to provide a 
comprehensive review of instruments that have been used to measure caregiver 
burden and social support in autism. METHODS: A systematic literature review 
was conducted from January 2002 - December 2012 using the databases: Medline, 
PsychINFO, Cochrane, Mental measurements year book and Health and 
psychosocial instruments to identify instruments. The psychometric properties 
of the instruments have been assessed. Inclusion / exclusion criteria that were 
applied to the study are: language, availability of full text articles, and relevance 
to the topic of study. RESULTS: The review also yielded 20 instruments for 
measuring social support. Of these, 19 were generic and 1 was condition-specific. 
The most common domains included in the instruments were: instrumental 
support and emotional support. Some instruments consisted of domains based 
on source of social support such as informal support from friends, family and 
spouse. A review of the psychometric properties of these instruments indicated 
good reliability (Cronbach’s alpha 0.7 – 0.95). Caregiver burden has been studied 
less frequently as compared to social support. Caregiver burden was mostly 
measured using 4 instruments. Of these four instruments, Caregiver Strain 
Questionnaire has been validated in a population of parents of autistic children. 
It has good reliability (Cronbach’s alpha 0.75 – 0.93) CONCLUSIONS: Caregiver 
burden and social support are two important constructs that affect the quality of 
life (QoL) of caregivers of children with autistic disorder. Consideration of the 
nature and extent of caregiver burden and social support will also facilitate the 
development of appropriate interventions that can help improve caregivers’ 
quality of life (QoL) and functioning.  
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OBJECTIVES: This study investigates impairments and propensities for risky 
behaviors among adults diagnosed with attention-deficit/hyperactivity disorder 
(ADHD) in Europe (E) and the United States (US). METHODS: Data are from a web-
based survey of adults who self-report having an ADHD diagnosis. Data were 
gathered October-December 2012 in Germany, UK, Netherlands, Sweden and the 
U.S. Participants were asked questions regarding social, family, educational and 
work-related impairments and risky personal behaviors previously shown to be 
common among adults with ADHD. Chi-square tests of proportions were used to 
test for significant differences between European and U.S. participants reported 
below. RESULTS: Three hundred European and 100 US adults reporting a 
diagnosis of ADHD from a health care professional completed the survey online. 
60% of both European and US respondents agreed that ADHD has had a negative 
impact on their career success. Over one-in-four respondents reported a 
suspension some time during school (31% E vs. 23% US; p<0.05). Twenty-six 
percent of European respondents reported 3 or more traffic tickets within the 
past year (vs. 9% US; p<.05); 11% reported 3 or more automobile accidents during 
the same period (vs. 9% US). Eighteen percent of Europeans also reported having 
had more than three job-related accidents or injuries requiring medical attention 
during this period (vs. 2 % US; p<0.05). Over 40% of study participants reported 
illegal drug use at some time in the past (44% E vs. 48% US), with around 10% 
reporting citations for driving under the influence of alcohol or drugs (15% E vs. 9 
% US) or serving time in prison (11% each). Concern about exposure to a sexually 
transmitted disease was reported by 34% European and 44% US (p<0.05) study 
participants. CONCLUSIONS: ADHD Adults from Europe and the US report 
various impairments and risky behaviors possibly related to their condition, 
some more frequent among European than US participants.  
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OBJECTIVES: The impact of MDD on HRQOL is well documented, but little 
information exists about commonly used HRQoL instruments’ adherence to EMA 
requirements for psychometric properties and content relevance. This work 
examines commonly used HRoQL instruments for their relevance to MDD, based 
on their content, concepts measured and psychometric properties, and use in 
published MDD studies. METHODS: A qualitative research paper provided a 
conceptual model for MDD (1). The SF-36 Health Survey (SF-36), Sheehan 
Disability Scale (SDS), Quality of Life Enjoyment and Satisfaction Questionnaire 
(Q-LES-Q), Health Status Questionnaire-12 (HSQ-12) and EuroQol (EQ-5D) were 
mapped to this conceptual model to examine their relevance to MDD. The 
measures’ reliability, validity, responsiveness to change in depression and use in 
MDD trials and labelling were examined through review of classic databases 
(including: PROQOLID, PROLABEL, MEDLINE, PSYCHINFO, FDA, EMA). Where no 
information on MDD was available, data for mood disorders were explored. 
RESULTS: The SF-36, SDS, Q-LES-Q and EQ-5D have been widely used in MDD, 
with SDS and Q-LES-Q results included as part of approved EMA labelling claims 
in mood disorder indications. These instruments are clinically well established 
and the combination covers HRQoL concepts relevant to the MDD population 
[emotional/social/physical (specifically bodily pain)]; Q-LES-Q and SF-36 are the 
most comprehensive HRQoL measures. All instruments met EMA psychometric 
requirements for validity, reliability and responsiveness to changes in depressive 
symptoms and in elderly populations for the HSQ-12. Furthermore, the 
instruments have been linguistically validated for use in many countries. 
CONCLUSIONS: These commonly used instruments are relevant to MDD and 
meet EMA criteria for reliability, validity and responsiveness. Thus, we conclude 
that these instruments are appropriate for use in clinical programmes to assess 
the impact of MDD treatment on HRQoL and overall functioning, particularly to 
support claims in Europe.  
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OBJECTIVES: To build a conceptual model describing disease experience in 
adolescent ADHD (aged 13–17) and impact of treatment, in order to inform the 
development of a measurement strategy to evaluate interventions. Conceptual 
models that summarize key concepts in describing disease experience are useful 
for developing strategies to measure meaningful treatment outcomes. 
Adolescents are increasingly participating in making decisions about their health 
care. Hence, it is important to evaluate outcomes that are meaningful to them. 
METHODS: In preparation for patient interviews, focused searches of databases, 
clinical and regulatory guidelines, ADHD specific tools and conference abstracts 
were conducted as part of the literature review to identify concepts to 
understand the experiences of adolescents with ADHD from various 
perspectives. In addition, concept elicitation interviews with 10 clinicians, 3 
teachers, 10 peers and 10 siblings of adolescents with ADHD were conducted 
using semi-structured guides. Results from this preliminary stage were analyzed 
systematically; transcripts from the peer and sibling interviews were analyzed 
using a pre-defined coding dictionary, to identify concepts for the model. 
RESULTS: Disease-defining concepts in ADHD included core ADHD symptoms, 
